Policy & Regulation
Calliditas partner initiates Phase 3 trial of Nefecon for IgA nephropathy in Japan
4 July 2024 -

Swedish biopharma company Calliditas Therapeutics AB (STO:CALTX) announced on Thursday that its partner Viatris Pharmaceutical Japan G.K. has initiated a Phase 3 clinical trial of Nefecon (VR-205) in Japanese patients with IgA nephropathy (IgAN).

The bridging study in Japan requires a limited number of Japanese patients and mirrors the design of the global NefIgArd trial.

A type of kidney disease, IgA nephropathy is a serious condition that affects an estimated 33,000 patients in Japan, with limited treatment options.